Thanks to the witnesses for being here today.
Dr. Mildon, in your presentation you touched on the modification of section 14, I believe it was, of the FDA, the Food and Drugs Act, with regard to the administration of sample drugs by registered nurses and nurse practitioners, I believe. We just went through a study on prescription drug abuse that identified a lot of flaws in the system, shall we say. I want to get your read on that, and probably that of Mr. Fisher as well. With regard to the sample drugs that are handed out by the big pharmacare people, it's normally an aggressive marketing process that they go through. They're providing a new drug into the market on a sample basis, and sometimes, if not all the time, the risks are higher than with the known drugs.
I'm curious to know, from the perspective of the registered nurses and nurse practitioners, if they're given the authority to hand out a sample drug, what information they would provide with regard to that sample drug. If they believe the sample drug is not applicable to that patient, would they refuse to provide it?